A study of hepatitis C treatment access in Los Angeles County found that obstacles arose both in people’s lives and in the health system. In the peer-reviewed study published in PLOS ONE, Shikha Handa and colleagues examined program data and interviews to understand why some residents did not reach treatment and what helped others engage with care.
From October 2024 to January 2025, the researchers analyzed de-identified records for 344 people contacted through Project HCV Connect, a county linkage-to-cure program. About half—168 people, or 49%—had already been treated, while 176 had not. Overall, 54% of the case-residents reported experiencing barriers. Among the 91 who reported specific barriers, personal factors were most common (43%), followed by provider-related barriers (31%), insurance barriers (13%) and inadequate access to medical care (13%). The analysis used descriptive statistics; it did not test whether barriers differed significantly across demographic groups.
Interviews with 10 program participants—seven who had not been treated and three who had—helped explain what those categories meant in daily life. Untreated participants described high costs, language difficulties, transportation problems, limited information about hepatitis C and trouble navigating the health system. Some accounts also pointed to provider follow-up and access: participants described long waits or difficulty completing steps needed to reach treatment. These accounts add detail to the program data, but the small interview group cannot represent everyone seeking care in the county.
The treated interviewees described barriers that could overlap: homelessness, incarceration, drug addiction and long waits to see a provider. Those experiences show how unstable circumstances and delays in care can complicate treatment, even when people eventually receive it. The study did not measure how often each experience occurs across the county.
Participants also described factors that supported treatment access. Untreated interviewees spoke about personal motivation and the importance of support from family, community and providers. Treated participants identified family support, trust in a provider, insurance coverage, understanding treatment’s benefits and wanting to avoid stigma as helpful. These are reported experiences, not evidence that any one factor guarantees treatment or that a specific intervention will work for everyone.
The access gap matters because chronic hepatitis C can be cured with oral antiviral treatment, yet a diagnosis does not ensure that a person reaches care. The study’s findings point to several possible areas for local action: the authors suggest considering language support, patient navigation and care coordination, mobile clinics for people experiencing homelessness, continuity of treatment for people returning to the community after incarceration, and fewer insurance restrictions. The study did not evaluate these strategies, so their effectiveness remains to be established.
The authors describe the findings as exploratory. The small, uneven interview sample may not reflect the wider Los Angeles County population, and low counts in some barrier categories prevented inferential analysis. The results offer a local account of where treatment access can break down and what participants said helped, rather than a countywide estimate of every barrier or a test of solutions.